Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma

被引:22
作者
Chang, James M. [1 ]
McCullough, Ann E. [2 ]
Dueck, Amylou C. [3 ]
Kosiorek, Heidi E. [3 ]
Ocal, Idris T. [2 ]
Lidner, Thomas K. [2 ]
Gray, Richard J. [1 ]
Wasif, Nabil [1 ]
Northfelt, Donald W. [4 ]
Anderson, Karen S. [4 ,5 ]
Pockaj, Barbara A. [1 ]
机构
[1] Mayo Clin, Dept Surg, Phoenix, AZ 85054 USA
[2] Mayo Clin, Dept Pathol, Phoenix, AZ USA
[3] Mayo Clin, Biostat Sect, Phoenix, AZ USA
[4] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[5] Arizona State Univ, Biodesign Inst, Tempe, AZ USA
关键词
DX RECURRENCE SCORE; PATHOLOGICAL PROGNOSTIC FACTORS; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; PATIENTS YOUNGER; ACTIVITY INDEX; FOLLOW-UP; PROLIFERATION; REPRODUCIBILITY;
D O I
10.1245/s10434-015-4616-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Newer multigene molecular profiling assays for breast carcinoma rely heavily on the quantification of genes of proliferation, whereas traditional histological grading reports the mitotic count. The mitotic activity of invasive breast carcinomas may be undervalued; therefore, an evaluation of the prognostic significance of mitotic score in predicting prognosis was performed. Methods. Retrospective analysis of a single institutional cohort of newly diagnosed estrogen receptor positive (ER+), HER2 negative (HER2-) unilateral invasive breast carcinomas was performed. Mitotic scores from the 3-part Nottingham combined histological grade were compared with clinical parameters. Mitoses were counted on Olympus BX50 microscopes and assigned scores of 1-3 based on observed mitoses. Results. A total of 1292 ER+, HER2- invasive breast carcinoma patients were identified, with a median followup time of 2.6 years (range 0-14 years). Higher mitotic score was significantly associated with younger age, larger tumor size, angiolymphatic invasion, node-positive disease, higher stage, and the use of hormonal and cytotoxic chemotherapy. Mitotic score was significant in modeling time to local/regional recurrence (p = 0.02), recurrencefree survival/RFS (p < 0.001), and overall survival/OS (p = 0.01) with higher mitotic scores associated with worse outcomes. Higher mitotic score correlated significantly with intermediate/high risk Oncotype Dx recurrence scores (p = 0.009). Conclusions. First-generation molecular profiling assays for estrogen receptor positive invasive breast carcinomas derive much of their predictive power from quantifying genes of proliferation into a single score. Sometimes overlooked in the profusion of molecular data, the time-tested, mitotic count in the Nottingham combined histological grade is a good single-parameter predictor of survival.
引用
收藏
页码:S509 / S515
页数:7
相关论文
共 37 条
  • [21] 2-E
  • [22] Routine Histopathologic Characteristics Can Predict Oncotype DX™ Recurrence Score in Subsets of Breast Cancer Patients
    Mattes, Malcolm D.
    Mann, Justin M.
    Ashamalla, Hani
    Tejwani, Ajay
    [J]. CANCER INVESTIGATION, 2013, 31 (09) : 604 - 606
  • [23] Prognostic relevance of mitotic activity in patients with node-negative breast cancer
    Medri, L
    Volpi, A
    Nanni, O
    Vecci, AM
    Mangia, A
    Schittulli, F
    Padovani, F
    Giunchi, DC
    Vito, A
    Amadori, D
    Paradiso, A
    Silvestrini, R
    [J]. MODERN PATHOLOGY, 2003, 16 (11) : 1067 - 1075
  • [24] Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index:: reproducibility of grade and advantages of proliferation index
    Meyer, JS
    Alvarez, C
    Milikowski, C
    Olson, N
    Russo, I
    Russo, J
    Glass, A
    Zehnbauer, BA
    Lister, K
    Parwaresch, R
    [J]. MODERN PATHOLOGY, 2005, 18 (08) : 1067 - 1078
  • [25] Prognostic factors in node-negative breast cancer - A review of studies with sample size more than 200 and follow-up more than 5 years
    Mirza, AN
    Mirza, NQ
    Vlastos, G
    Singletary, SE
    [J]. ANNALS OF SURGERY, 2002, 235 (01) : 10 - 26
  • [26] A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik, S
    Shak, S
    Tang, G
    Kim, C
    Baker, J
    Cronin, M
    Baehner, FL
    Walker, MG
    Watson, D
    Park, T
    Hiller, W
    Fisher, ER
    Wickerham, DL
    Bryant, J
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) : 2817 - 2826
  • [27] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Paik, Soonmyung
    Tang, Gong
    Shak, Steven
    Kim, Chungyeul
    Baker, Joffre
    Kim, Wanseop
    Cronin, Maureen
    Baehner, Frederick L.
    Watson, Drew
    Bryant, John
    Costantino, Joseph P.
    Geyer, Charles E., Jr.
    Wickerham, D. Lawrence
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) : 3726 - 3734
  • [28] PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .4. SHOULD YOU BE A TYPER OR A GRADER - A COMPARATIVE-STUDY OF 2 HISTOLOGICAL PROGNOSTIC FEATURES IN OPERABLE BREAST-CARCINOMA
    PEREIRA, H
    PINDER, SE
    SIBBERING, DM
    GALEA, MH
    ELSTON, CW
    BLAMEY, RW
    ROBERTSON, JFR
    ELLIS, IO
    [J]. HISTOPATHOLOGY, 1995, 27 (03) : 219 - 226
  • [29] Prognostic significance of Nottingham histologic grade in invasive breast carcinoma
    Rakha, Emad A.
    El-Sayed, Maysa E.
    Lee, Andrew H. S.
    Elston, Christopher W.
    Grainge, Matthew J.
    Hodi, Zsolt
    Blamey, Roger W.
    Ellis, Ian O.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3153 - 3158
  • [30] Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189
    Simpson, JF
    Gray, R
    Dressler, LG
    Cobau, CD
    Falkson, CI
    Gilchrist, KW
    Pandya, KJ
    Page, DL
    Robert, NJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) : 2059 - 2069